Induced pluripotent stem cells (iPSCs) have become a major focus of scientific research, with over 33,000 publications on the topic currently available on PubMed.gov, the world’s leading database for scientific literature. These cells, which are reprogrammed from differentiated somatic cells back to an embryonic-like state, have opened up new possibilities in regenerative medicine, drug development, and disease modeling. Since the groundbreaking discovery of iPSCs in 2006, the field has seen rapid expansion, with an increasing number of research products and technologies entering the market. To fully understand the competitive landscape of iPSC-based innovations, it is crucial to explore the growing presence of competitors and the advancements made in this dynamic space. [Read more…]
iPSC-Derived NK Cells and the Future of Immunotherapy
By Richard Boyd PhD and Alan Trounson PhD
Natural Killer (NK) cell therapies are rapidly emerging as a transformative force in healthcare, with promising potential across a range of conditions. They feature the complex killing capacity of classic immune system T cells but lack the prolonged time required for them to respond. With the armoury to rapidly detect and remove damaged, infected, senescent and cancerous cells throughout the body, they are nature’s frontline cell-mediated attack force. [Read more…]
REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research
The translation of stem cell therapies begins with a well-characterized and thoroughly documented starting cell source. REPROCELL’s StemRNA™ Clinical iPSC Seed Stock Clones offer cell therapy developers streamlined starting material that provides a gateway into early-stage clinical development. By combining regulatory alignment with ethical sourcing and footprint-free mRNA reprogramming, REPROCELL now offers various male and female, ready-to-use, clinical-grade iPSC lines manufactured in our facilities, in the U.S. and Japan. [Read more…]
Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm
A Japanese government bioethics panel has given the green light to a controversial but closely regulated area of research: the creation of human embryos using lab-generated sperm and eggs derived from pluripotent stem cells, including induced pluripotent stem (iPS) cells. The panel’s recommendation allows this practice strictly for scientific research focused on infertility and genetic diseases—not for reproductive purposes. [Read more…]
First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases
-
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases
-
Phase 1/2a trial, CLARICO, is a first-in-human, multisite, 2-part interventional trial to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001
-
Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in children and adults
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 79
- Next Page »